RU2564445C2 - Ингибиторы репликации вич - Google Patents

Ингибиторы репликации вич Download PDF

Info

Publication number
RU2564445C2
RU2564445C2 RU2013121788/04A RU2013121788A RU2564445C2 RU 2564445 C2 RU2564445 C2 RU 2564445C2 RU 2013121788/04 A RU2013121788/04 A RU 2013121788/04A RU 2013121788 A RU2013121788 A RU 2013121788A RU 2564445 C2 RU2564445 C2 RU 2564445C2
Authority
RU
Russia
Prior art keywords
methyl
mmol
compound
pyridin
added
Prior art date
Application number
RU2013121788/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2013121788A (ru
Inventor
Эндрю Саймон БЭЛЛ
Айан Брайан ГАРДНЕР
Дэвид Кемерон ПРАЙД
Флориан Мишель Уэйкенхат
Карл Ричард Гибсон
Original Assignee
ВииВ Хелткер ЮКей Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ВииВ Хелткер ЮКей Лимитед filed Critical ВииВ Хелткер ЮКей Лимитед
Publication of RU2013121788A publication Critical patent/RU2013121788A/ru
Application granted granted Critical
Publication of RU2564445C2 publication Critical patent/RU2564445C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
RU2013121788/04A 2010-11-15 2011-11-01 Ингибиторы репликации вич RU2564445C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41361810P 2010-11-15 2010-11-15
US61/413,618 2010-11-15
US201161485355P 2011-05-12 2011-05-12
US61/485,355 2011-05-12
PCT/IB2011/054852 WO2012066442A1 (en) 2010-11-15 2011-11-01 Inhibitors of hiv replication

Publications (2)

Publication Number Publication Date
RU2013121788A RU2013121788A (ru) 2014-12-27
RU2564445C2 true RU2564445C2 (ru) 2015-10-10

Family

ID=44999830

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013121788/04A RU2564445C2 (ru) 2010-11-15 2011-11-01 Ингибиторы репликации вич

Country Status (15)

Country Link
US (3) US8809363B2 (enExample)
EP (1) EP2640729B1 (enExample)
JP (2) JP5902704B2 (enExample)
CN (2) CN105330675A (enExample)
AR (1) AR083870A1 (enExample)
AU (2) AU2011330850B2 (enExample)
BR (1) BR112013011991A2 (enExample)
CA (1) CA2817896A1 (enExample)
CL (1) CL2013001338A1 (enExample)
MX (1) MX343274B (enExample)
RU (1) RU2564445C2 (enExample)
TW (1) TWI445709B (enExample)
UY (1) UY33729A (enExample)
WO (1) WO2012066442A1 (enExample)
ZA (1) ZA201303433B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
EP2588455B1 (en) 2010-07-02 2018-04-04 Gilead Sciences, Inc. 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds
CN103140474A (zh) 2010-07-02 2013-06-05 吉里德科学公司 治疗aids的萘-2-基乙酸衍生物
CA2817896A1 (en) * 2010-11-15 2012-05-24 Viiv Healthcare Uk Limited Inhibitors of hiv replication
KR20140003438A (ko) 2010-11-15 2014-01-09 카톨리에케 유니버시테이트 루벤 항바이러스성 축합 헤테로사이클릭 화합물
MX2013012266A (es) 2011-04-21 2013-11-22 Gilead Sciences Inc Compuestos de benzotiazol y su uso farmaceutico.
US9199959B2 (en) 2011-10-25 2015-12-01 Shionogi & Co., Ltd. HIV replication inhibitor
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
ES2571479T3 (es) 2012-04-20 2016-05-25 Gilead Sciences Inc Derivados del ácido benzotiazol-6-il acético y su uso para tratar una infección por VIH
US8906929B2 (en) 2012-08-16 2014-12-09 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
TW201441197A (zh) 2013-01-31 2014-11-01 Shionogi & Co Hiv複製抑制劑
JP2016516692A (ja) 2013-03-13 2016-06-09 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company ヒト免疫不全ウイルス複製の阻害剤
JP2016512511A (ja) 2013-03-13 2016-04-28 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company ヒト免疫不全ウイルス複製の阻害剤
US9655889B2 (en) 2013-03-13 2017-05-23 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
EP2970297A1 (en) 2013-03-14 2016-01-20 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2014159959A1 (en) 2013-03-14 2014-10-02 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
KR102345381B1 (ko) 2013-06-25 2021-12-29 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서 유용한 카르바졸 카르복스아미드 화합물
AR096721A1 (es) 2013-06-25 2016-01-27 Bristol Myers Squibb Co Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos
EP2821082A1 (en) 2013-07-05 2015-01-07 Laboratoire Biodim Method of producing an inactivated lentivirus, especially HIV, vaccine, kit and method of use
WO2015123230A1 (en) 2014-02-12 2015-08-20 Bristol-Myers Squibb Company Benzothiazole macrocycles as inhibitors of human immunodeficiency virus replication
EP3152215A1 (en) 2014-02-18 2017-04-12 ViiV Healthcare UK (No.5) Limited Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
WO2015126758A1 (en) 2014-02-18 2015-08-27 Bristol-Myers Squibb Company Imidazopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
US9409922B2 (en) 2014-02-18 2016-08-09 Bristol-Myers Squibb Company Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication
US9273067B2 (en) 2014-02-19 2016-03-01 Bristol-Myers Squibb Company Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
ES2687322T3 (es) 2014-02-19 2018-10-24 VIIV Healthcare UK (No.5) Limited Inhibidores de la replicación del virus de inmunodeficiencia humana
JP6579549B2 (ja) 2014-05-16 2019-09-25 塩野義製薬株式会社 Hiv複製阻害作用を有する3環性複素環誘導体
MX393057B (es) 2014-10-24 2025-03-24 Bristol Myers Squibb Co Compuestos de indol carboxamida útiles como inhibidores de cinasas.
TWI676618B (zh) 2014-10-24 2019-11-11 美商必治妥美雅史谷比公司 三環化合物
CN107108555B (zh) 2014-10-24 2020-12-01 百时美施贵宝公司 三环阻转异构体化合物
US10806734B2 (en) 2015-05-08 2020-10-20 Katholieke Universiteit Leuven Functional cure of retroviral infection
AU2016271762B2 (en) 2015-05-29 2020-01-23 Shionogi & Co., Ltd. Nitrogen-containing tricyclic derivatives having HIV replication inhibitory activity
CN111018912A (zh) * 2019-11-22 2020-04-17 苏州二叶制药有限公司 一种抗病毒药物关键中间体的合成和纯化方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2144033C1 (ru) * 1994-03-07 2000-01-10 Варнер-Ламберт Компани Производные бензотиофена, бензофурана, индолтиазепинона, оксазепинона и диазепинона, фармацевтическая композиция, обладающая ингибирующей клеточную адгезию или вич-активностью, способ торможения адгезии лейкоцитов к эндотелиальным клеткам при лечении вызванных ею болезней, способ лечения млекопитающих, зараженных вич
WO2005076861A2 (en) * 2004-02-04 2005-08-25 University Of Virginia Patent Foundation Compounds that inhibit hiv particle formation
RU2008137929A (ru) * 2008-09-24 2010-03-27 Александр Леонидович Гинцбург (RU) Биологически активные вещества, подавляющие патогенные бактерии и способ их получения
WO2010130842A1 (en) * 2009-05-15 2010-11-18 Katholieke Universiteit Leuven Thieno [2, 3-b] pyridine derivatives as viral replication inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
WO2002012189A1 (en) * 2000-08-09 2002-02-14 Mitsubishi Pharma Corporation Fused bicyclic amide compounds and medicinal use thereof
JP2003171381A (ja) 2001-09-25 2003-06-20 Takeda Chem Ind Ltd エントリー阻害剤
JP2003119137A (ja) 2001-10-10 2003-04-23 Japan Tobacco Inc Hiv阻害剤
CA2463975A1 (en) 2001-10-26 2003-05-01 Maria Emilia Di Francesco Dihydroxypyrimidine carboxamide inhibitors of hiv integrase
AU2002349675A1 (en) 2001-12-05 2003-06-17 Shionogi And Co., Ltd. Derivative having hiv integrase inhibitory activity
CA2469592C (en) 2001-12-12 2005-08-23 Bristol-Myers Squibb Company Hiv integrase inhibitors
US7763641B2 (en) 2001-12-21 2010-07-27 Tibotec Pharmaceuticals Ltd. Broadspectrum heterocyclic substituted phenyl containing sulfonamide HIV protease inhibitors
EP1467970B1 (en) 2002-01-17 2007-08-22 Merck & Co., Inc. Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors
TW200306192A (en) 2002-01-18 2003-11-16 Bristol Myers Squibb Co Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors
ES2324231T3 (es) * 2004-12-17 2009-08-03 F. Hoffmann-La Roche Ag Derivados de tieno-piridina como intensificadores alostericos de gaba-b.
KR20100108337A (ko) * 2007-11-15 2010-10-06 베링거 인겔하임 인터내셔날 게엠베하 사람 면역결핍 바이러스 복제의 억제제
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
WO2011076765A1 (en) 2009-12-23 2011-06-30 Katholieke Universiteit Leuven Novel antiviral compounds
CA2817896A1 (en) * 2010-11-15 2012-05-24 Viiv Healthcare Uk Limited Inhibitors of hiv replication
KR20140003438A (ko) 2010-11-15 2014-01-09 카톨리에케 유니버시테이트 루벤 항바이러스성 축합 헤테로사이클릭 화합물
US9029391B2 (en) 2011-01-24 2015-05-12 Viiv Healthcare Uk Limited Isoquinoline compounds and methods for treating HIV
JP6055468B2 (ja) 2011-07-15 2016-12-27 ヴィーブ ヘルスケア ユーケー リミテッド アザインドール化合物及びhivを治療するための方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2144033C1 (ru) * 1994-03-07 2000-01-10 Варнер-Ламберт Компани Производные бензотиофена, бензофурана, индолтиазепинона, оксазепинона и диазепинона, фармацевтическая композиция, обладающая ингибирующей клеточную адгезию или вич-активностью, способ торможения адгезии лейкоцитов к эндотелиальным клеткам при лечении вызванных ею болезней, способ лечения млекопитающих, зараженных вич
WO2005076861A2 (en) * 2004-02-04 2005-08-25 University Of Virginia Patent Foundation Compounds that inhibit hiv particle formation
RU2008137929A (ru) * 2008-09-24 2010-03-27 Александр Леонидович Гинцбург (RU) Биологически активные вещества, подавляющие патогенные бактерии и способ их получения
WO2010130842A1 (en) * 2009-05-15 2010-11-18 Katholieke Universiteit Leuven Thieno [2, 3-b] pyridine derivatives as viral replication inhibitors

Also Published As

Publication number Publication date
RU2013121788A (ru) 2014-12-27
JP2013542247A (ja) 2013-11-21
CL2013001338A1 (es) 2014-03-28
AU2011330850B2 (en) 2016-01-28
CN103429595A (zh) 2013-12-04
AU2016202565A1 (en) 2016-05-19
TWI445709B (zh) 2014-07-21
US8809363B2 (en) 2014-08-19
EP2640729A1 (en) 2013-09-25
UY33729A (es) 2012-06-29
CN103429595B (zh) 2015-10-21
JP2016164163A (ja) 2016-09-08
BR112013011991A2 (pt) 2016-08-30
MX2013005486A (es) 2013-12-12
JP5902704B2 (ja) 2016-04-13
TW201300395A (zh) 2013-01-01
AU2011330850A1 (en) 2013-06-27
US20120136023A1 (en) 2012-05-31
ZA201303433B (en) 2014-12-23
US20160355528A1 (en) 2016-12-08
WO2012066442A1 (en) 2012-05-24
AR083870A1 (es) 2013-03-27
US9447116B2 (en) 2016-09-20
US20140315927A1 (en) 2014-10-23
CN105330675A (zh) 2016-02-17
CA2817896A1 (en) 2012-05-24
MX343274B (es) 2016-10-31
EP2640729B1 (en) 2016-12-21

Similar Documents

Publication Publication Date Title
JP5902704B2 (ja) Hiv複製の阻害剤
KR101483834B1 (ko) 항바이러스 화합물
JP5925394B2 (ja) 抗レトロウイルス剤としての(ヘテロ)アリールアセトアミド誘導体
US9132129B2 (en) Antiviral compounds
US9096586B2 (en) Therapeutic compounds
AU2014205315B2 (en) Therapeutic compounds for the treatment of viral infections
JP5372751B2 (ja) Aza−ペプチドプロテアーゼ阻害剤
ES2574831T3 (es) Inhibidores de la proteasa antivirales
US20140296266A1 (en) Therapeutic compounds
US20160272635A1 (en) Substituted dihydropyrido[3,4-b]pyrazinones as dual inhibitors of bet proteins and polo-like kinases
US20090075939A1 (en) Novel HIV reverse transcriptase inhibitors
HK1173994A (en) Novel antiviral compounds
JP2006225388A (ja) ピペラジン誘導体
WO2006085199A1 (en) Piperazine derivatives

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20181102